TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2666293
Drug: Ranitidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (2 150 mg tablets at night)
Study: 1234507
Drug: Intramuscular salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular salbutamol (8 mug/kg)
Study: 1234507
Drug: Intramuscular salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular salbutamol (4 mug/kg)
Study: 1234507
Drug: Intramuscular salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular salbutamol (12 mug/kg)
Study: 28343658
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment (control group)
Study: 17054107
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel (Lan ATG) 120 mg every 6 weeks
Study: 17054107
Drug: Lanreotide microparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide microparticles (Lan MP) 60 mg every 3 weeks
Study: 14510743
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (1 g)
Study: 21715702
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg)
Study: 9024246
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bromocriptine, cyproheptadine, and valproic acid
Study: 3056447
Drug: Capozide (captopril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capozide (captopril, 25 mg with 15 mg hydrochlorothiazide)
Study: 27566475
Drug: Ultrasound-guided injections
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injections
Study: 27566475
Drug: Blind injections
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injections
Study: 19862000
Drug: Chemotherapy (vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (vinorelbine and gemcitabine followed by docetaxel, or paclitaxel and carboplatin)
Study: 16856621
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon (peg‐INF)‐alpha2a 180 microg/week plus ribavirin 800 mg/d for 12 weeks, followed by extended treatment for 72 weeks (extension arm)
Study: 16856621
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (12 weeks)
Study: 16856621
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon (peg‐INF)‐alpha2a 180 microg/week plus ribavirin 800 mg/d for 12 weeks, followed by additional 12 or 36 weeks depending on genotype for those achieving EVR
Study: 12538787
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition and 20 mL breast milk/kg/d (BM)
Study: 12538787
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition and 20 mL formula/kg/d (F)
Study: 12538787
Drug: Solely parenteral
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solely parenteral nutrition (C)
Study: 9055140
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of H1 blocker dimetindene maleate (0.1 mg/kg) and H2 blocker cimetidine (5 mg/kg)
Study: 3314726
Drug: Human pituitary
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human pituitary growth hormone
Study: 26082504
Drug: Efavirenz with
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz with daily rifapentine and isoniazid
Study: 20085176
Drug: Black cohosh-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh-containing preparations
Study: 18295937
Drug: Beer (633
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (633 ml)
Study: 18295937
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (264 ml)
Study: 18295937
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (264 ml)
Study: 18295937
Drug: Whisky (79
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whisky (79 ml)
Study: 16923409
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous mononuclear bone marrow cells
Study: 16923409
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of peripheral mononuclear blood cells
Study: 14638501
Drug: Intranasal ruprintrivir
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ruprintrivir (8 mg) prophylaxis 5x/day for 5 days
Study: 14638501
Drug: Intranasal ruprintrivir
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ruprintrivir (8 mg) prophylaxis 2x/day for 5 days
Study: 14638501
Drug: Intranasal ruprintrivir
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ruprintrivir (8 mg) treatment 5x/day for 4 days
Study: 14638501
Drug: Intranasal ruprintrivir
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ruprintrivir treatment
Study: 10814771
Drug: Haloperidol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (both doses)
Study: 8891147
Drug: Clarithromycin (CLA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (CLA; 500 mg given twice daily for nine doses)
Study: 8891147
Drug: Azithromycin (AZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (AZ; 500 mg for the first dose and then 250 mg once daily for four doses)
Study: 1642616
Drug: high dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose intravenous immunoglobulin
Study: 31888234
Drug: Amaranth oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amaranth oil (20 mL)
Study: 31888234
Drug: Rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed oil (20 mL)
Study: 23506245
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous insulin (target blood glucose 80‐130 mg/dL, 4·44‐7·21 mmol/L) for up to 72 h
Study: 23506245
Drug: Standard sliding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sliding scale subcutaneous insulin (blood glucose range 80‐179 mg/dL, 4·44‐9·93 mmol/L) for up to 72 h
Study: 15746735
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker therapy with oral diltiazem 120 mg/daily
Study: 15746735
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium channel blocker therapy
Study: 16958094
Drug: Ropinirole monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole monotherapy
Study: 1369705
Drug: Nicardipine 60-90
Normalized name: nicardipine hydrochloride 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 60-90 mg/day (n = 9)
Study: 23294168
Drug: 0.5% carmellose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% carmellose sodium with added lipid (Drop C‐L)
Study: 23294168
Drug: 1.0% glycerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% glycerine with added lipid (Drop G‐L)
Study: 11710858
Drug: Unilateral autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral autologous platelet-rich plasma wound treatment (APG) during standard deep-plane rhytidectomy
Study: 28821365
Drug: Morphine 0.1mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1mg/kg and ketamine 0.15mg/kg (MK group)
Study: 28821365
Drug: Morphine 0.1mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1mg/kg and placebo (MP group)
Study: 27256093
Drug: Sequential capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab)
Study: 27256093
Drug: Combination CapeOX/mFOLFOX6-Bmab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination CapeOX/mFOLFOX6-Bmab
Study: 25540041
Drug: Telephone-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based intervention (four weekly 30-minute calls and written resources)
Study: 14554218
Drug: etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: etanercept (25 mg s.q., twice/week)
Study: 1555624
Drug: L-propionylcarnitine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionylcarnitine 600 mg i.v. single bolus
Study: 1555624
Drug: L-carnitine 500
Normalized name: L-Carnitine 500mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 500 mg i.v. equimolar dose
Study: 1555624
Drug: L-propionylcarnitine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionylcarnitine and L-carnitine
Study: 2934779
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (0.2 mg)
Study: 18576902
Drug: Intranasal haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal haloperidol 2.5 mg (2.5 mg/0.1‐ml spray into a single naris)
Study: 18576902
Drug: Intravenous haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous haloperidol 2.5 mg (0.5 ml of 5.0 mg/ml) infused over 15 minutes
Study: 18576902
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol 2.5 mg (0.5 ml of 5.0 mg/ml)
Study: 18576902
Drug: Intranasal haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal haloperidol 2.5 mg
Study: 18576902
Drug: Intranasal haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal haloperidol
Study: 2556725
Drug: ACTH 4‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH 4‐10 (1 mg)
Study: 10420094
Drug: ACTH 4‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH 4‐10 (1 mg/day over 6 weeks)
Study: 10420094
Drug: Desacetyl‐α‐MSH (1.68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desacetyl‐α‐MSH (1.68 mg)
Study: 10420094
Drug: Desacetyl‐α‐MSH (subchronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desacetyl‐α‐MSH (subchronic treatment)
Study: 8937121
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg, p.o., qam, daily for 6 weeks)
Study: 8937121
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg, p.o., qam, daily for 6 weeks) plus Amoxicillin (1500 mg, p.o, t.i.d., daily for 2 weeks)
Study: 8937121
Drug: Lansoprazole and
Normalized name: Lansoprazole and naproxen only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole and Amoxicillin combination
Study: 22286364
Drug: Calcium-modified orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-modified orange juice (1.6 g/l of calcium) (C+)
Study: 22286364
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice with 0.4 g/l of calcium from calcium lactate pentahydrate (Ca)
Study: 22286364
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice with 0.2 g/l of linear sodium polyphosphate (LPP)
Study: 22286364
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium and LPP (Ca+LPP)
Study: 20133491
Drug: Tenecteplase (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (2 mg)
Study: 9850939
Drug: Idebenone 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone 90 mg tid for 24 months
Study: 9850939
Drug: Idebenone 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone 120 mg tid for 24 months
Study: 9850939
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 months followed by idebenone 90 mg tid for another 12 months
Study: 7989621
Drug: SofScale pre-scaling
Approvals — FDA: no, EMA: no, PMDA: no
Description: SofScale pre-scaling gel
Study: 3059235
Drug: Penbutolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 40 mg once daily
Study: 19332211
Drug: Universal beta-blockade
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal beta-blockade (UBB; n = 197) comprising an algorithm‐based, nurse‐led strategy to optimize dosing and adherence to bisoprolol titration over > or =1 week preoperatively
Study: 19332211
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC; n = 203) whereby beta-blockers are continued in those already taking them or prescribed for patients identified as high risk based on ischemia
Study: 15764956
Drug: Nutrition with
Normalized name: pediatric nutrition with iron, lactose free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition with 10 mg of OX administered orally twice a day
Study: 15764956
Drug: Nutrition alone
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition alone (NA) with placebo pills
Study: 10486791
Drug: Combined esterified
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined esterified estrogen-methyltestosterone therapy (0.625 mg esterified estrogen + 1.25 mg methyltestosterone or 1.25 mg esterified estrogen + 2.5 mg methyltestosterone)
Study: 7493415
Drug: High-dose phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose phentolamine (0.3 +/- 0.1 degrees C)
Study: 7493415
Drug: Medium-dose phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose phentolamine (0.2 +/- 0.0 degrees C)
Study: 7493415
Drug: Low-dose phentolamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose phentolamine (0.1 +/- 0.0 degrees C)
Study: 7493415
Drug: High-dose phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose phentolamine (0.6 +/- 1 degrees C)
Study: 7493415
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of phentolamine
Study: 7493415
Drug: Medium and
Normalized name: blood pressure test kit medium and large cuffs MISCELL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium and high doses of phentolamine
Study: 1903846
Drug: Conjugate vaccine
Normalized name: meningococcal conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate vaccine consisting of H. influenzae type b polysaccharide and Neisseria meningitidis OMPC
Study: 12809330
Drug: Conjugate vaccine
Normalized name: meningococcal conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate vaccine
Study: 6263476
Drug: Crossover therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover therapy with VM‐26 or ascorbic acid
Study: 30794296
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy exercise (n=96)
Study: 29581079
Drug: Insulin-sensitizing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitizing therapy (thiazolidinediones)
Study: 29581079
Drug: Insulin-providing therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-providing therapy (insulin, sulfonylurea, or a meglitinide)
Study: 21992111
Drug: Galantamine fast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine fast titration (8 mg/week increments to 16-24 mg)
Study: 21992111
Drug: Galantamine slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine slow titration (8 mg/4 weeks to 16-24 mg)
Study: 21992111
Drug: Galantamine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (both titration arms)
Study: 17156148
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 6-methyl-prednisolone (1 mg/kg/day)
Study: 17156148
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 6-methyl-prednisolone (1 mg/kg/day)
Study: 16301269
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (EF; 15 mL of 1% ropivacaine plus 100 mug fentanyl)
Study: 16301269
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl (IF; 15 mL of 1% ropivacaine plus 2 mL of normal saline followed by IV injection of 100 mug fentanyl)
Study: 16301269
Drug: Control (C;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (C; 15 mL of 1% ropivacaine plus 2 mL of normal saline followed by IV injection of 2 mL of normal saline)
Study: 12184473
Drug: Available therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available therapies for endometriosis
Study: 25839348
Drug: 3% diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diquafosol ophthalmic solution with high-WC CL
Study: 25839348
Drug: 3% diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diquafosol ophthalmic solution with low-WC CL
Study: 21537155
Drug: Octreotide 25
Normalized name: octreotide 2500 mcg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 25 μg/hr
Study: 21537155
Drug: Octreotide 50
Normalized name: octreotide 50 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 50 μg/hr
Study: 16226163
Drug: Atorvastatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 80 mg
Study: 18413554
Drug: Pravastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin, 40 mg
Study: 9861125
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg bolus at induction followed by droperidol 0.1 mg per 1 mg of morphine
Study: 9861125
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg bolus at induction followed by ondansetron 0.32 mg per 1 mg of morphine
Study: 7652039
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light treatment (2500-3000 1x)
Study: 7652039
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light treatment (> 500 1x)
Study: 7652039
Drug: Full-spectrum white
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-spectrum white light treatment
Study: 7652039
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light treatment
Study: 2668253
Drug: Norfloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (200 mg) and amphotericin B (500 mg), twice daily
Study: 29392071
Drug: Intranasal splint
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal splint with airway
Study: 27136909
Drug: Trametinib pediatric
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib pediatric oral solution
Study: 27136909
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of trametinib
Study: 22561972
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg·kg(‐1) of body weight, administered 60 minutes before exercise)
Study: 19099919
Drug: Pulmonary thromboendarterectomy
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary thromboendarterectomy (PTE) therapy (Group A)
Study: 15082480
Drug: Adalimumab 20
Normalized name: ADALIMUMAB 20MG/0.4ML INJ SYRINGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 20 mg every other week
Study: 21285171
Drug: Adalimumab 20
Normalized name: ADALIMUMAB 20MG/0.4ML INJ SYRINGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 20 mg weekly
Study: 11822223
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg once daily for 6 days
Study: 11822223
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg b.i.d. for 14 days
Study: 11330365
Drug: Azithromycin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1.0 g single dose
Study: 11822223
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg b.i.d. for 7 days
Study: 27492064
Drug: 24-hour antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour antibiotic regimen
Study: 27492064
Drug: 5-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day antibiotic regimen
Study: 2658361
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (Control)
Study: 17061019
Drug: iv arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv arginine (ARG, 0.5 g/kg)
Study: 17061019
Drug: oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral protein load (PRO, 50 g)
Study: 17061019
Drug: iv lipid‐heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv lipid‐heparin infusion (Li He, Intralipid 10% 250 ml)